Самидорфан и оланзапин

Topline results from a phase 2 study show that treatment with a novel oral antipsychotic was as effective as treatment with the antipsychotic olanzapine (multiple brands) with far less weight gain in patients with schizophrenia, the company developing the drug announced today.
The drug currently known as ALKS 3831, from Alkermes, combines samidorphan, a novel, potent mu-opioid antagonist, with olanzapine.

Positive Topline Phase 2 Results for Novel Schizophrenia Drug